Xeris Biopharma Holdings
XERS
134 hedge funds and large institutions have $136M invested in Xeris Biopharma Holdings in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 24 closing their positions.
361% more call options, than puts
Call options by funds: $932K | Put options by funds: $202K
54% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 35
2% more capital invested
Capital invested by funds: $134M → $136M (+$2.51M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.24% less ownership
Funds ownership: 43.16% → 40.91% (-2.2%)
6% less funds holding
Funds holding: 143 → 134 (-9)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$1.34M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.2M |
| 3 |
BlackRock
New York
|
+$749K |
| 4 |
Renaissance Technologies
New York
|
+$690K |
| 5 |
Morgan Stanley
New York
|
+$643K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.48M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.32M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$926K |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$687K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$500K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
151
Crystalline Management
Montreal, Quebec,
Canada
| – | -$36.6K | -16,573 | Closed |
|
|
AAS
152
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$18.6K | -10,000 | Closed |
|
|
MLICM
153
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$8.99K | -4,068 | Closed |
|
|
EC
154
EntryPoint Capital
New York
| – | -$8.76K | -3,963 | Closed |
|
|
FDCDDQ
155
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$1.26K | -570 | Closed |
|
156
Comerica Bank
Dallas,
Texas
| – | -$922 | -417 | Closed |
|
|
SWA
157
SOA Wealth Advisors
New York
| – | -$261 | -118 | Closed |
|
|
AWM
158
Avior Wealth Management
Omaha,
Nebraska
| – | -$59 | -27 | Closed |
|
XERS Hedge Fund Activity: Q2 2024 in Review
134 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2024, worth a combined $136M — up 1.9% from $134M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of XERS and 16 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 54 added.
The largest buyer was MPM BioImpact, adding an estimated $1.34M. The largest seller was Ameriprise, cutting an estimated $1.48M.
- 134 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2024, down from 143 in Q1 2024.
- Funds reported $136M of Xeris Biopharma Holdings stock for Q2 2024, up 1.9% quarter-over-quarter.
- 16 funds opened new Xeris Biopharma Holdings positions in Q2 2024 and 24 closed out, a net change of -8 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2024 was MPM BioImpact, an estimated $1.34M added.
- The largest Xeris Biopharma Holdings seller in Q2 2024 was Ameriprise, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2024.